GlassScriptPhysician profile
Souheil E Saba
NPI 1225011711
$10,053.17
in general payments reported to CMS, 2019-2025
33 companies · $1,990 in 2025
The $1,990 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,179 · 2020: $1,039 · 2021: $964 · 2022: $1,545 · 2023: $1,773 · 2024: $1,564 · 2025: $1,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,326.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,208.50 | 2019-2025 | Amplatzer Amulet, Ensite Precision, Thoratec Heartmate 3 Lvas Implant Kit |
| Amgen INC. | $823.74 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $535.72 | 2021-2025 | In.Pact Admiral, Symplicity G3 |
| Novartis Pharmaceuticals Corporation | $395.77 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $334.86 | 2019-2025 | Lifevest |
| Philips North America LLC | $314.36 | 2020-2025 | IV Other |
| Chiesi USA, INC. | $312.98 | 2020-2025 | Kengreal, Cleviprex |
| Boston Scientific Corporation | $304.89 | 2020-2025 | Avvigo Guidance System |
| Kestra Medical Technology Services, INC. | $267.92 | 2022-2025 | Assure Wcd |
| Medtronic Vascular, INC. | $237.94 | 2019-2020 | |
| Abiomed | $214.85 | 2022 | |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Inari Medical, INC. | $158.42 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Stryker Corporation | $150.00 | 2025 | Artix Mt |
| E.R. Squibb & Sons, L.L.C. | $143.56 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $142.57 | 2024 | Penumbra System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.35 | 2019 | |
| Merck Sharp & Dohme LLC | $134.77 | 2022-2025 | Verquvo |
| Pfizer INC. | $129.65 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $129.42 | 2019-2022 | |
| Heartflow, INC. | $106.91 | 2019-2024 | Ffrct |
| Siemens Medical Solutions USA, INC. | $98.17 | 2019-2020 | |
| Ancora Heart, INC. | $98.11 | 2023 | Accucinch |
| Novo Nordisk INC | $79.56 | 2021-2025 | Wegovy |
| Opsens INC. | $76.70 | 2022 | |
| Janssen Pharmaceuticals, INC | $75.53 | 2019 | |
| Edwards Lifesciences Corporation | $72.29 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $54.23 | 2023 | Inpefa |
| Bridgebio Pharma, INC. | $35.32 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $22.97 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $19.93 | 2024 | Arcalyst |
| Cordis US Corp. | $19.45 | 2025 | Mynx Control Venous |
| Akcea Therapeutics, INC. | $16.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Souheil Saba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.